Table 1.
Baseline characteristics of patients.
| Patient Characteristics | Number of Cases (n = 61) | |
|---|---|---|
| Age (median, range) | 65 (40–84) | |
| Sex | Male | 34 (55.7%) |
| Female | 27 (44.3%) | |
| ECOG | 0 | 17 (27.9%) |
| 1 | 31 (50.8%) | |
| 2 | 10 (16.4%) | |
| 3 | 3 (4.9%) | |
| 1st line treatment | Gemcitabine | 3 (4.9%) |
| Gemcitabine/nab-paclitaxel | 39 (63.9%) | |
| Gemcitabine/nab-paclitaxel/FOLFOX | 4 (6.6%) | |
| FOLFIRINOX | 11 (18%) | |
| No treatment | 4 (6.6%) | |
| Survival | Alive | 19 (31.1%) |
| Dead | 42 (68.9%) | |
| Disease progression | Yes | 45 (73.8%) |
| No | 11 (18%) | |
| Not valuable (No treatment or surgery) | 5 (8.2%) | |
| Tissue availability | Yes | 43 (70.5%) |
| No (Cytology) | 18 (29.5%) | |
| Primary tumor location | Tail | 17 (27.9%) |
| Body | 25 (41%) | |
| Head | 18 (29.5%) | |
| Body-Tail | 1 (1.6%) | |
| Number of metastatic lesions | One location | 26 (42.6%) |
| More than one location | 35 (57.4%) | |
| Metastatic lesions location | Hepatic lesions | 48 (78.7%) |
| Non-hepatic lesions | 13 (21.3%) | |
| Tissue Biopsy RAS status 1 | RAS mutated | 33 (76.7%) |
| RAS wild-type | 10 (23.3%) | |
| Liquid Biopsy RAS status | RAS mutated | 47 (77%) |
| RAS wild-type | 14 (23%) |
1 For the analysis of RAS mutational status, primary tumor tissue was available in 70.5% (43/61) of patients.